Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARγ ligand pioglitazone

Hideaki Nakaya, Barbara D. Summers, Andrew C. Nicholson, Antonio M. Gotto, David P. Hajjar, Jihong Han

Research output: Contribution to journalArticle

26 Scopus citations

Abstract

Thiazolidinediones, a class of drugs for the treatment of type-2 diabetes, are synthetic ligands for peroxisome proliferator-activated receptor-γ. They have been demonstrated to possess cardioprotective effects in humans and anti-atherogenic properties in animal models. However, the question remains whether a peroxisome proliferator-activated receptor-γ ligand can reverse the development of atherosclerosis. In this study, we tested the effects of pioglitazone on the development of established atherosclerosis in low-density lipoprotein receptor-null mice. We observed that atherosclerosis in low-density lipoprotein receptor-null mice progressed when mice were fed a high-fat diet. Pioglitazone treatment of atherogenic mice prevented this progression of atherosclerosis from its middle stages of disease, but was not able to reverse it. Withdrawal of the high-fat diet from mice with advanced atherosclerosis did not result in a reduction in lesion sizes. Pioglitazone treatment also had no effect on advanced atherosclerosis. Levels of high density lipoprotein cholesterol correlated inversely with lesion development when pioglitazone was given during lesion progression. However, pioglitazone had no effect on circulating high density lipoprotein levels in mice in which treatment was initiated following 14 weeks on the high-fat diet. These findings have implications for the analysis of therapeutic agents in murine models of atherosclerosis and the use of pioglitazone in patients with established atherosclerosis.

Original languageEnglish (US)
Pages (from-to)2007-2014
Number of pages8
JournalAmerican Journal of Pathology
Volume174
Issue number6
DOIs
StatePublished - Jun 2009

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARγ ligand pioglitazone'. Together they form a unique fingerprint.

Cite this